製品番号: HY-P3211

Nangibotide

(別名: LR12)

8 Cited Publications

カスタマーレビュー

Based on 8 publication(s) in Google Scholar

Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.53%
CAS 番号: 2014384-91-7
分子式: C₅₄H₈₂N₁₄O₂₂S₂
分子量:1343.44

保管条件:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Nangibotide 構造式

CAS 番号: 2014384-91-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (8)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

TREM-1 receptor<^[1]

TREM receptor アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

NOD-like Receptor (NLR) アイソフォーム固有の製品をすべて表示 :

Interleukin Related アイソフォーム固有の製品をすべて表示 :

体外実験

Nangibotide (50-100 μg/mL) significantly reverses TNF-α-induced inhibition of osteogenic differentiation, increasing alkaline phosphatase activity, calcium nodule formation, and Runx2, Osterix mRNA, and COL1A1 protein expression in MC3T3-E1 mouse osteoblasts^[2].
Nangibotide (10 ng/mL) promotes LO2 cell proliferation indirectly via CCL20 secretion from macrophages^[3].
Nangibotide (25-100 μg/mL; 24 h) significantly suppresses Porphyromonas gingivalis LPS (HY-D1056D)-induced TREM-1 mRNA, membrane-bound TREM-1, and soluble sTREM-1 expression in human primary monocytes, reducing IL-8, TNF-α, and IL-1β secretion^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Nangibotide (5 mg/kg; i.p.; every 2 days for 4 weeks) significantly attenuates cartilage degradation, improves subchondral bone microarchitecture, and inhibits osteoblast apoptosis in mice with ACLT-induced osteoarthritis^[2].
Nangibotide (5 mg/kg; i.v.; 1 h after TAA injection) promotes liver repair by improving the resolution of inflammation and liver regeneration in mice with Thioacetamide (HY-Y0698)-induced acute liver failure^[3].
Nangibotide (5 mg/kg; i.v.; single dose 2 h before LPS) alleviates lung inflammation (reduced MPO activity), decreases lung wet/dry weight ratio, and inhibits NLRP3 inflammasome activation (lower NLRP3 protein expression) in mice with LPS (from E. coli O111:B4) (HY-D1056A1)-induced acute lung injury^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 male mice (2-month-old; ACLT-induced osteoarthritis)^[2]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection; every 2 days for 4 weeks
Result:

Showed lower OARSI score.
Showed lower MMP-13 expression.
Increased MAR and BFR/BS.
Decreased cleaved-caspase3 positive cells.

Animal Model:

BALB/c male mice (6-8-week-old; TAA-induced ALF)^[3]
Dosage:

5 mg/kg
Administration:

Intravenous injection; single dose 1 h after TAA
Result:

Decreased liver necrosis.
Reduced inflammatory cell infiltration.
Upregulated CCL20 secretion from macrophages, and activated p38 MAPK pathway in hepatocytes.

化学情報

CAS 番号 2014384-91-7
性状 Solid
分子量 1343.44
分子式 C₅₄H₈₂N₁₄O₂₂S₂
Color White to off-white
別名

LR12
シーケンスの短縮

LQEEDAGEYGCM-NH2
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (8)

All In Vivo Efficacy StudyBio/Physico-chemical AssayWBHistological Imaging/StainingIFFlow Cytometry

Sort by:

Journal Impact Factor

J Pharm Anal

2026 Jan 6.
J Headache Pain

Microglia TREM1-mediated neuroinflammation contributes to central sensitization via the NF-κB pathway in a chronic migraine model. [Abstract]

2024 Jan 5;25(1):3. PMID: 38177990
Atherosclerosis

TREM-1 inhibition with LR12 attenuates in-stent neoatherosclerosis through modulating macrophage polarization in a rabbit model: An optical coherence tomography study. [Abstract]

2026 Apr:415:120701. PMID: 41832836
Int Immunopharmacol

Rheumatoid arthritis synovial fibroblasts promote the glycolysis of myeloid-derived suppressor cells via TREM1/mTOR axis. [Abstract]

2026 Sep 1:184:116961. PMID: 42242136
Int Immunopharmacol

Triggering receptor expressed on myeloid cells-1 aggravates obliterative bronchiolitis via enhancing the proinflammatory phenotype of macrophages. [Abstract]

2024 Sep 30;143(Pt 1):113274. PMID: 39353383
Cell Signal

Inhibition of TREM-1 ameliorates angiotensin II-induced atrial fibrillation by attenuating macrophage infiltration and inflammation through the PI3K/AKT/FoxO3a signaling pathway. [Abstract]

2024 Dec:124:111458. PMID: 39384003

Nangibotide purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Dec:124:111458. [Abstract]

Nangibotide TFA (LR12, 5 mg/kg; i.p.; once daily for 4 weeks). Quantification of AF inducibility (n = 10) and AF duration (n = 6) in each group.

Nangibotide purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Dec:124:111458. [Abstract]

Nangibotide TFA (LR12, 5 mg/kg; i.p.; once daily for 4 weeks). Representative electrophysiological mapping images of the atria during sinus rhythm. Bars indicate the time from the first to the last measurement during one heartbeat. Arrows display the direction of electrical conduction on the atrial surface.

Nangibotide purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Dec:124:111458. [Abstract]

Nangibotide TFA (LR12, 5 mg/kg; i.p.; once daily for 4 weeks). Representative Western blot images of Cx40 and Cx43 in mouse atrial tissue.

Nangibotide purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Dec:124:111458. [Abstract]

Nangibotide TFA (LR12, 5 mg/kg; i.p.; once daily for 4 weeks). Representative images displaying Masson's trichrome staining, highlighting blue-stained areas indicative of fibrosis (upper scale bar = 80 μm, lower scale bar = 40 μm). The black arrows indicate regions of fibrosis.

Nangibotide purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Dec:124:111458. [Abstract]

Nangibotide TFA (LR12, 5 mg/kg; i.p.; once daily for 4 weeks). Representative images of immunofluorescence staining for CD68 (green), TREM-1 (red), and DAPI (blue) in mouse atrial tissue (bar = 10 μm). The white arrowsindicate regions of co-localization of TREM-1 with CD68.

Nangibotide purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Dec:124:111458. [Abstract]

Nangibotide TFA (LR12, 5 mg/kg; i.p.; once daily for 4 weeks). The expression of TREM-1 in macrophages, and the M1/M2 ratio in mouse atria were analyzed using flow cytometry (n = 6).
PLoS One

Inhibition of TREM1 attenuates myocardial ischemia-reperfusion injury-induced cardiomyocyte pyroptosis by suppressing the activation of the NF-κB signaling pathway. [Abstract]

2026 Jan 9;21(1):e0340382. PMID: 41511954
Stanford University

2025.

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (37.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7444 mL

3.7218 mL

7.4436 mL

5 mM

0.1489 mL

0.7444 mL

1.4887 mL

10 mM

0.0744 mL

0.3722 mL

0.7444 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Cuvier V, et, al. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol. 2018 Oct;84(10):2270-2279. [Content Brief]

[2]. Zhong Y, et al. Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis and TGF-β activity in subchondral bone. Inflammopharmacology. 2022 Jun;30(3):1107-1117. [Content Brief]

[3]. Wang Y, et al. LR12 Promotes Liver Repair by Improving the Resolution of Inflammation and Liver Regeneration in Mice with Thioacetamide- (TAA-) Induced Acute Liver Failure. Mediators Inflamm. 2021 May 28;2021:2327721. [Content Brief]

[4]. Dubar M, et al. Effects of Porphyromonas gingivalis LPS and LR12 peptide on TREM-1 expression by monocytes. J Clin Periodontol. 2018 Jul;45(7):799-805. [Content Brief]

[5]. Liu T, et al. Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation. Sci Rep. 2016 Dec 22;6:39473. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.7444 mL	3.7218 mL	7.4436 mL	18.6089 mL
	5 mM	0.1489 mL	0.7444 mL	1.4887 mL	3.7218 mL
	10 mM	0.0744 mL	0.3722 mL	0.7444 mL	1.8609 mL
	15 mM	0.0496 mL	0.2481 mL	0.4962 mL	1.2406 mL
	20 mM	0.0372 mL	0.1861 mL	0.3722 mL	0.9304 mL
	25 mM	0.0298 mL	0.1489 mL	0.2977 mL	0.7444 mL
	30 mM	0.0248 mL	0.1241 mL	0.2481 mL	0.6203 mL

Keywords

Nangibotide

8 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Nangibotide

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Peptide Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Peptide Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Pattern Recognition Receptors Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Nangibotide

TREM receptor アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示

NOD-like Receptor (NLR) アイソフォーム固有の製品をすべて表示

Interleukin Related アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (8)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Nangibotide 関連分類

HY-P3211 関連分類